MPM: Firefly Bio Launches With $94 Million To Treat Cancer With Degrader Antibody Conjugates

Firefly Bio announced it emerged from stealth mode with a $94 million Series A financing co-led by founding investor Versant Ventures and by MPM BioImpact along with Decheng Capital and with participation from Eli Lilly & Company. Firefly has developed a novel platform to treat cancer using degrader antibody conjugates (DACs). The post Firefly Bio Launches With $94 Million To Treat Cancer With Degrader Antibody Conjugates appeared first on Pulse 2.0.